AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick-CSF (QCSF)
Description: A fast contrast sensitivity measurement method using a Bayesian algorithm.
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelli-Robson
Description: A standard method developed using a Sloan-letter chart with decreasing contrast.
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optec 6500
Description: A standard test using sinusoidal gratings to measure the contrast sensitivity function.
Study NCT03479853 — intervention group
Intervention type: PROCEDURE
Intervention: Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)
Description: Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
Study NCT04465253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care occupational therapy
Study NCT04465253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participate in discussions via videoconferencing
Study NCT04465253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participate in interview via videoconferencing
Study NCT04465253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04465253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03934138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational movie on placebo mechanisms
Description: Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)
Study NCT03934138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Informative movie on hand washing
Description: Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
Study NCT01470053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate plus azelastine HCl
Study NCT01470053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Study NCT01470053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine HCl
Study NCT02402673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Temporary activity modification and graded exercises
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
Study NCT00860639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemtuzumab ozogamycin
Description: gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
Study NCT01022203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Approach Therapy
Description: The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
Study NCT02323451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Chitosan
Description: intra-articular injection
Study NCT01022203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Family Education
Description: The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
Study NCT04576013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
Study NCT04576013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
Study NCT04576013 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Description: Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
Study NCT04576013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive upper extremity motor training
Study NCT04576013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive upper extremity motor training
Study NCT04576013 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive upper extremity motor training
Study NCT03949881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FEMJA transplatation
Description: The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
Study NCT03556995 — intervention group
Intervention type: OTHER
Intervention: bariatric surgery patients
Study NCT01042340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calogen® - an energy dense oleic acid based formula
Description: A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
Study NCT03874793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study NCT03874793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study NCT04584814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Basal analysis
Study NCT04584814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scare ventilator at 20
Description: To set scare ventilator by 20 cycles per minute
Study NCT02323451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate Injection
Description: intra-articular injection
Study NCT03866798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: Immune Globulin, intravenous, human-ifas
Study NCT00836745 — intervention group
Intervention type: OTHER
Intervention: Non Interventional
Description: Sutent capsule, once daily administered per the locally approved product information.
Study NCT04584814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scare ventilator at 40
Description: To set scare ventilator by 40 cycles per minute
Study NCT01628562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol 50 mcg/kg/min
Study NCT01628562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil 0.5 mcg/kg/min
Study NCT02450045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block
Study NCT02450045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture
Study NCT03930862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator Attachment (positioner)
Description: intra oral attachment
Study NCT03930862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator Attachment (positioner)
Description: intra oral attachment
Study NCT01552603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control Software
Description: This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
Study NCT02961803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100 mg capsule
Study NCT02961803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100 mg capsule
Study NCT02961803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02811406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Receives IV albumin infusion
Description: IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.
Study NCT02811406 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Do not receive IV albumin infusion
Description: No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated.
Study NCT02898077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02898077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT02898077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study NCT02510898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week Writing to Heal course
Description: During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Intravenous and oral repeating dose
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous and oral repeating dose
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administed at a dose and as per schedule in arm description
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as per schedule in arm description
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
Study NCT00626197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
Study NCT04333251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-titer anti-Sars-CoV-2 plasma
Description: Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer >1:64 vs best supportive care
Study NCT00611806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid 2mg po daily
Study NCT00611806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B12
Description: B12 400 micrograms po daily
Study NCT00611806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule po daily
Study NCT00903643 — intervention group
Intervention type: OTHER
Intervention: Physical examination
Description: Physical examination and multiple questionnaires will be administered
Study NCT00631293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactisole
Description: administration of lactisole followed by placebo
Study NCT00631293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo followed by lactisole
Study NCT01505777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 10/mosapride 10mg three times a day, P.O. 4week
Study NCT01505777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 15/mosapride 10mg three times a day, P.O. 4week
Study NCT04333251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen therapy
Description: oxygen therapy
Study NCT03605576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling
Description: Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions.
Study NCT03605576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study NCT02021552 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: 5 ml blood sampling
Study NCT00847067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: 3ml 1% Ropivacaine at each level T1 - T5
Study NCT00847067 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injections
Description: Sham injections with Normal Saline
Study NCT00864201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
Study NCT04100876 — intervention group
Intervention type: GENETIC
Intervention: Global DNA methylation will be quantified in the DNA samples by colorimetry
Description: Global DNA methylation will be quantified in the DNA samples by colorimetry
Study NCT03825731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC022
Description: GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
Study NCT02651857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® Colonoscope
Description: Endoscopic diagnostic procedures for lower GI tract
Study NCT02651857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® Gastroscope
Description: Endoscopic diagnostic procedures for upper GI tract
Study NCT02126761 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted, trivalent subunit influenza vaccine
Description: Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
Study NCT02126761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
Study NCT02126761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 3 is experimental with double the usual antigen dosage
Study NCT02126761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine
Description: Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
Study NCT01057329 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: mg according to body weight
Study NCT01057329 — intervention group
Intervention type: DRUG
Intervention: Duloxetine
Description: 30 mg / die
Study NCT01057329 — intervention group
Intervention type: DRUG
Intervention: Olanzapine
Description: 5mg 1 wwek and 10 mg from second week